phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"10.37489/2588-0527-2024-2-19-28BXQLYJphgenomics-289Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫCURRENT REVIEWФармакогенетические особенности назначения ингибиторов ангиотензинпревращающего ферментаPharmacogenetic features of angiotensin-converting enzyme inhibitorshttps://orcid.org/0000-0003-3278-2556КантемироваБ. И.KantemirovaB. I.

Кантемирова Бэла Исмаиловна — д. м. н., профессор, профессор кафедры фармакологии

Астрахань 

Bela I. Kantemirova — PhD, Dr. Sci. (Med.), Professor, Professor of the Department of Pharmacology

Astrakhan 

belakantemirova@rambler.ruhttps://orcid.org/0000-0001-7011-0932КомароваО. В.KomarovaO. V.

Комарова Ольга Владимировна — аспирант кафедры фармакологии 

Астрахань 

Olga V. Komarova — Post graduate of the Department of Pharmacology 

Astrakhan 

https://orcid.org/0000-0002-6564-3408РомановаА. Н.RomanovaA. N.

Романова Александра Николаевна — аспирант кафедры фармакологии 

Астрахань 

Aleksandra N. Romanova — Post-graduate of the Department of Pharmacology 

Astrakhan 

ФГБОУ ВО «Астраханский медицинский университет»РоссияAstrakhan State Medical UniversityRussian Federation202431122024021928Copyright © Кантемирова Б.И., Комарова О.В., Романова А.Н., 20242024Кантемирова Б.И., Комарова О.В., Романова А.Н.Kantemirova B.I., Komarova O.V., Romanova A.N.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/289

Интерес к проблеме рационального назначения лекарственных препаратов с учётом генетических особенностей пациента усиливается с каждым годом. Зарубежная медицина наиболее часто использует фармакогенетическое тестирование — как основной инструмент для подбора индивидуальной терапии. Наибольший интерес проявлен к генам-кандидатам, участвующим в изменении фармакологического ответа на терапию у пациентов с сердечно-сосудистыми заболеваниями, в связи с высоким риском смертности. В большинстве случаев нарушения в сердечно-сосудистой системе сопровождаются высоким артериальным давлением, для снижения которого используют группу ингибиторов АПФ. Но полученные данные по эффективности и безопасности применения препаратов разнятся в зависимости от пола, расы или этнической принадлежности пациентов, что приводит к усложнению разработки единого алгоритма внедрения фармакогенетических тестов в клиническую практику. Авторы данного обзора предприняли попытку систематизировать данные, полученные из различных исследований, и выявить наличие клинически значимых корреляций между изменением эффективности ингибиторов АПФ и наличием полиморфизма генов-кандидатов ренин-ангиотензин-альдостероновой системы.

Interest in the rational prescription of medicines, considering the genetic characteristics of patients, is increasing every year. In foreign medicine, pharmacogenetic testing is often used as the main tool for selecting individual therapy. The most significant interest has been shown in candidate genes involved in changing the pharmacological response to therapy in patients with cardiovascular diseases because of the high risk of mortality. In most cases, cardiovascular disorders are accompanied by high blood pressure, which can be reduced using ACE inhibitors. However, data on the effectiveness and safety of drug use vary depending on the gender, race, or ethnicity of patients, making it more difficult to develop a unified algorithm for the introduction of pharmacogenetic tests into clinical practice. The authors of this review attempted to systematize the data obtained from various studies and identify the presence of clinically significant correlations between changes in the effectiveness of ACE inhibitors and the presence of polymorphism of candidate genes of the renin-angiotensin-aldosterone system.

фармакогенетикаполиморфизм геновингибиторы АПФартериальная гипертензияpharmacogeneticsgene polymorphismACE inhibitorsarterial hypertensionReferencesКолбин А.С., Радаева К.С., Мотринчук А.Ш., Свечкарева И.Р. Тренды в клинической фармакологии согласно публикациям в международных и российских специализированных журналах. Качественная клиническая практика. 2024;(2):33-42. https://doi.org/10.37489/2588-0519-2024-2-33-42. EDN: LYNKOFKolbin AS, Radaeva KS, Motrinchuk AS, Svechkareva IR. Trends in clinical pharmacology as represented by international and specialized journals. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2024;(2):33-42. (In Russ.). https://doi.org/10.37489/2588-0519-2024-2-33-42. EDN: LYNKOFПрикладная фармакогенетика / Ш. П. Абдуллаев, А. С. Аметов, А. В. Боярко [и др.]. – Москва: ООО "Издательство "Триада", 2021. – 496 с. ISBN 978-5-94789-982-5. EDN: PXWCTD.Applied pharmacogenetics / ShP Abdullaev, AS Ametov, AV Boyarko [et al]. Moscow: Triada Publishing House, LLC, 2021. (In Russ.). ISBN 978-5-94789-982-5. EDN: PXWCTD.Василевский И.В. Взаимодействие лекарство – ген и фармакологический ответ. МЕЖДУНАРОДНЫЕ ОБЗОРЫ: клиническая практика и здоровье. 2020;(1):7-19. EDN: DCWUTP.Vasilevski IV. Drug – gene interaction and pharmacotherapeutic response. Mezhdunarodnye obzory klinicheskaya praktika i zdorovie. 2020;(1):7-19. (In Russ.). EDN: DCWUTP.Moick S, Sommer I, Gartlehner G. WHO-Leitlinie: Leitfaden für die medikamentöse Behandlung von Bluthochdruck bei Erwachsenen [WHO Guideline for the Pharmacological Treatment of Hypertension in Adults]. Gesundheitswesen. 2023 Feb;85(2):139-142. German. https://doi.org/10.1055/a-1989-1745.Moick S, Sommer I, Gartlehner G. WHO-Leitlinie: Leitfaden für die medikamentöse Behandlung von Bluthochdruck bei Erwachsenen [WHO Guideline for the Pharmacological Treatment of Hypertension in Adults]. Gesundheitswesen. 2023 Feb;85(2):139-142. German. https://doi.org/10.1055/a-1989-1745.Драпкина О.М., Васильева Л.Э. Спорные вопросы применения ингибиторов ангиотензин превращающего фермента и антагонистов рецепторов ангиотензина у пациентов с COVID-19. Кардиоваскулярная терапия и профилактика. 2020;19(3):2580. https://doi.org/10.15829/1728-8800-2020-2580.Drapkina OM, Vasilyeva LE. Debatable points of using angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in patients with COVID-19. Cardiovascular Therapy and Prevention. 2020;19(3):2580. (In Russ.). https://doi.org/10.15829/1728-8800-2020-2580.Chen YY, Liu D, Zhang P, et al. Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors. J Hum Hypertens. 2016 Dec;30(12):766-771. https://doi.org/10.1038/jhh.2016.24.Chen YY, Liu D, Zhang P, et al. Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors. J Hum Hypertens. 2016 Dec;30(12):766-771. https://doi.org/10.1038/jhh.2016.24.Fan X, Wang Y, Sun K, et al. Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. Clin Pharmacol Ther. 2007 Aug;82(2):187-96. https://doi.org/10.1038/sj.clpt.6100214Fan X, Wang Y, Sun K, et al. Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. Clin Pharmacol Ther. 2007 Aug;82(2):187-96. https://doi.org/10.1038/sj.clpt.6100214Fan Z, Wu G, Yue M, et al. Hypertension and hypertensive left ventricular hypertrophy are associated with ACE2 genetic polymorphism. Life Sci. 2019 May 15;225:39-45. https://doi.org/10.1016/j.lfs.2019.03.059.Fan Z, Wu G, Yue M, et al. Hypertension and hypertensive left ventricular hypertrophy are associated with ACE2 genetic polymorphism. Life Sci. 2019 May 15;225:39-45. https://doi.org/10.1016/j.lfs.2019.03.059.Zi-Yang Y, Nanshan X, Dongling L, et al. ACE2 gene polymorphisms are associated with elevated pulmonary artery pressure in congenital heart diseases. Gene. 2023 Oct 5;882:147642. https://doi.org/10.1016/j.gene.2023.147642.Zi-Yang Y, Nanshan X, Dongling L, et al. ACE2 gene polymorphisms are associated with elevated pulmonary artery pressure in congenital heart diseases. Gene. 2023 Oct 5;882:147642. https://doi.org/10.1016/j.gene.2023.147642.Luo Y, Liu C, Guan T, et al. Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in south Xinjiang. Hypertens Res. 2019 May;42(5):681-689. https://doi.org/10.1038/s41440-018-0166-6. Epub 2018 Dec 12. Erratum in: Hypertens Res. 2019 May;42(5):744. https://doi.org/10.1038/s41440-019-0205-y.Luo Y, Liu C, Guan T, et al. Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in south Xinjiang. Hypertens Res. 2019 May;42(5):681-689. https://doi.org/10.1038/s41440-018-0166-6. Epub 2018 Dec 12. Erratum in: Hypertens Res. 2019 May;42(5):744. https://doi.org/10.1038/s41440-019-0205-y.Al-Eitan L, Al-Khaldi S, Ibdah RK. ACE gene polymorphism and susceptibility to hypertension in a Jordanian adult population. PLoS One. 2024 Jun 25;19(6):e0304271. https://doi.org/10.1371/journal.pone.0304271.Al-Eitan L, Al-Khaldi S, Ibdah RK. ACE gene polymorphism and susceptibility to hypertension in a Jordanian adult population. PLoS One. 2024 Jun 25;19(6):e0304271. https://doi.org/10.1371/journal.pone.0304271.Heidari F, Vasudevan R, Mohd Ali SZ, et al. Association of insertion/ deletion polymorphism of angiotensin-converting enzyme gene among Malay male hypertensive subjects in response to ACE inhibitors. J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):872-9. https://doi.org/10.1177/1470320314538878.Heidari F, Vasudevan R, Mohd Ali SZ, et al. Association of insertion/ deletion polymorphism of angiotensin-converting enzyme gene among Malay male hypertensive subjects in response to ACE inhibitors. J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):872-9. https://doi.org/10.1177/1470320314538878.He H, Li LM, Cao WH, et al. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril. Ann Hum Biol. 2005 Jan-Feb;32(1):30-43. https://doi.org/10.1080/03014460400027458.He H, Li LM, Cao WH, et al. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril. Ann Hum Biol. 2005 Jan-Feb;32(1):30-43. https://doi.org/10.1080/03014460400027458.Bhatnagar V, O'Connor DT, Schork NJ, et al. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007 Oct;25(10):2082-92. https://doi.org/10.1097/HJH.0b013e3282b9720e.Bhatnagar V, O'Connor DT, Schork NJ, et al. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007 Oct;25(10):2082-92. https://doi.org/10.1097/HJH.0b013e3282b9720e.Irvin MR, Lynch AI, Kabagambe EK, et al. Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. J Hypertens. 2010 Oct;28(10):2076-83. https://doi.org/10.1097/HJH.0b013e32833c7a4d.Irvin MR, Lynch AI, Kabagambe EK, et al. Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. J Hypertens. 2010 Oct;28(10):2076-83. https://doi.org/10.1097/HJH.0b013e32833c7a4d.Altmaier E, Menni C, Heier M, et al. The Pharmacogenetic Footprint of ACE Inhibition: A Population-Based Metabolomics Study. PLoS One. 2016 Apr 27;11(4):e0153163. https://doi.org/10.1371/journal.pone.0153163.Altmaier E, Menni C, Heier M, et al. The Pharmacogenetic Footprint of ACE Inhibition: A Population-Based Metabolomics Study. PLoS One. 2016 Apr 27;11(4):e0153163. https://doi.org/10.1371/journal.pone.0153163.da Agostini L, Cunha WR, Silva NNT, et al. Angiotensin-converting enzyme gene (ACE) polymorphisms are associated with dysregulation of biochemical parameters in hypertensive patients. Mol Biol Rep. 2023 Feb;50(2):1487-1497. https://doi.org/10.1007/s11033-022-08128-z.da Agostini L, Cunha WR, Silva NNT, et al. Angiotensin-converting enzyme gene (ACE) polymorphisms are associated with dysregulation of biochemical parameters in hypertensive patients. Mol Biol Rep. 2023 Feb;50(2):1487-1497. https://doi.org/10.1007/s11033-022-08128-z.Charoen P, Eu-Ahsunthornwattana J, Thongmung N, et al. Contribution of Four Polymorphisms in Renin-Angiotensin-AldosteroneRelated Genes to Hypertension in a Thai Population. Int J Hypertens. 2019 Aug 14;2019:4861081. https://doi.org/10.1155/2019/4861081.Charoen P, Eu-Ahsunthornwattana J, Thongmung N, et al. Contribution of Four Polymorphisms in Renin-Angiotensin-AldosteroneRelated Genes to Hypertension in a Thai Population. Int J Hypertens. 2019 Aug 14;2019:4861081. https://doi.org/10.1155/2019/4861081.Mabhida SE, Mashatola L, Kaur M, et al. Hypertension in African Populations: Review and Computational Insights. Genes (Basel). 2021 Apr 6;12(4):532. https://doi.org/10.3390/genes12040532.Mabhida SE, Mashatola L, Kaur M, et al. Hypertension in African Populations: Review and Computational Insights. Genes (Basel). 2021 Apr 6;12(4):532. https://doi.org/10.3390/genes12040532.Su X, Lee L, Li X, et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensinconverting enzyme inhibitor. Circulation. 2007 Feb 13;115(6):725-32. https://doi.org/10.1161/CIRCULATIONAHA.106.642058.Su X, Lee L, Li X, et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensinconverting enzyme inhibitor. Circulation. 2007 Feb 13;115(6):725-32. https://doi.org/10.1161/CIRCULATIONAHA.106.642058.Yu H, Lin S, Zhong J, et al. A core promoter variant of angiotensinogen gene and interindividual variation in response to angiotensin-converting enzyme inhibitors. J Renin Angiotensin Aldosterone Syst. 2014 Dec;15(4):540-6. https://doi.org/10.1177/1470320313506481.Yu H, Lin S, Zhong J, et al. A core promoter variant of angiotensinogen gene and interindividual variation in response to angiotensin-converting enzyme inhibitors. J Renin Angiotensin Aldosterone Syst. 2014 Dec;15(4):540-6. https://doi.org/10.1177/1470320313506481.Woodiwiss AJ, Nkeh B, Samani NJ, et al. Functional variants of the angiotensinogen gene determine antihypertensive responses to angiotensinconverting enzyme inhibitors in subjects of African origin. J Hypertens. 2006 Jun;24(6):1057-64. https://doi.org/10.1097/01.hjh.0000226195.59428.57.Woodiwiss AJ, Nkeh B, Samani NJ, et al. Functional variants of the angiotensinogen gene determine antihypertensive responses to angiotensinconverting enzyme inhibitors in subjects of African origin. J Hypertens. 2006 Jun;24(6):1057-64. https://doi.org/10.1097/01.hjh.0000226195.59428.57.Shlyk SV, Drobotya NV, Khaisheva LA, et al. Effectiveness of personalized selection of antihypertensive therapy based on genetic polymorphism. European Heart Journal, Volume 41, Issue Supplement_2, November 2020, ehaa946.2760. https://doi.org/10.1093/ehjci/ehaa946.2760.Shlyk SV, Drobotya NV, Khaisheva LA, et al. Effectiveness of personalized selection of antihypertensive therapy based on genetic polymorphism. European Heart Journal, Volume 41, Issue Supplement_2, November 2020, ehaa946.2760. https://doi.org/10.1093/ehjci/ehaa946.2760.Rysz J, Franczyk B, Rysz-Górzyńska M, Gluba-Brzózka A. Pharmacogenomics of Hypertension Treatment. Int J Mol Sci. 2020 Jul 1;21(13):4709. https://doi.org/10.3390/ijms21134709Rysz J, Franczyk B, Rysz-Górzyńska M, Gluba-Brzózka A. Pharmacogenomics of Hypertension Treatment. Int J Mol Sci. 2020 Jul 1;21(13):4709. https://doi.org/10.3390/ijms21134709Fontana V, Luizon MR, Sandrim VC. An update on the pharmacogenetics of treating hypertension. J Hum Hypertens. 2015 May;29(5):283-91. doi: 10.1038/jhh.2014.76.Fontana V, Luizon MR, Sandrim VC. An update on the pharmacogenetics of treating hypertension. J Hum Hypertens. 2015 May;29(5):283-91. doi: 10.1038/jhh.2014.76.Brugts JJ, de Maat MP, Danser AH, Boersma E, Simoons ML. Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association (PERGENE) study. Neth Heart J. 2012 Jan;20(1):24-32. doi: 10.1007/s12471-011-0173-6.Brugts JJ, de Maat MP, Danser AH, Boersma E, Simoons ML. Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association (PERGENE) study. Neth Heart J. 2012 Jan;20(1):24-32. doi: 10.1007/s12471-011-0173-6.Brugts JJ, Boersma E, Simoons ML. Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit. Pharmacogenomics. 2010 Aug;11(8):1115-26. doi: 10.2217/pgs.10.103.Brugts JJ, Boersma E, Simoons ML. Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit. Pharmacogenomics. 2010 Aug;11(8):1115-26. doi: 10.2217/pgs.10.103.Lee JK, Wu CK, Tsai CT, et al. Genetic variation-optimized treatment benefit of angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: a 12-year follow-up study. Pharmacogenet Genomics. 2013 Apr;23(4):181-9. doi: 10.1097/FPC.0b013e32835a0ffa.Lee JK, Wu CK, Tsai CT, et al. Genetic variation-optimized treatment benefit of angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: a 12-year follow-up study. Pharmacogenet Genomics. 2013 Apr;23(4):181-9. doi: 10.1097/FPC.0b013e32835a0ffa.Oemrawsingh RM, Akkerhuis KM, Van Vark LC, et al. Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model. J Am Heart Assoc. 2016 Mar 28;5(3):e002688. doi: 10.1161/JAHA.115.002688.Oemrawsingh RM, Akkerhuis KM, Van Vark LC, et al. Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model. J Am Heart Assoc. 2016 Mar 28;5(3):e002688. doi: 10.1161/JAHA.115.002688.Luo JQ, He FZ, Wang ZM, et al. SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril)-Induced Cough: a Pharmacogenetic Study. Sci Rep. 2015 Nov 26;5:17253. doi: 10.1038/srep17253.Luo JQ, He FZ, Wang ZM, et al. SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril)-Induced Cough: a Pharmacogenetic Study. Sci Rep. 2015 Nov 26;5:17253. doi: 10.1038/srep17253.Maeda K, Ieiri I, Yasuda K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan,and temocapril. Clin Pharmacol Ther. 2006 May;79(5):427-39. doi: 10.1016/j.clpt.2006.01.011.Maeda K, Ieiri I, Yasuda K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan,and temocapril. Clin Pharmacol Ther. 2006 May;79(5):427-39. doi: 10.1016/j.clpt.2006.01.011.Ramsey LB, Gong L, Lee SB, et al. PharmVar GeneFocus: SLCO1B1. Clin Pharmacol Ther. 2023 Apr;113(4):782-793. doi: 10.1002/cpt.2705.Ramsey LB, Gong L, Lee SB, et al. PharmVar GeneFocus: SLCO1B1. Clin Pharmacol Ther. 2023 Apr;113(4):782-793. doi: 10.1002/cpt.2705.Abbes H, Zubiaur P, Soria-Chacartegui P, et al. SLCO1B1 and ABCG2 genotype-informed phenotypes are related to variation in ramipril exposure. Basic Clin Pharmacol Toxicol. 2024 Sep;135(3):295-307. doi: 10.1111/bcpt.14046.Abbes H, Zubiaur P, Soria-Chacartegui P, et al. SLCO1B1 and ABCG2 genotype-informed phenotypes are related to variation in ramipril exposure. Basic Clin Pharmacol Toxicol. 2024 Sep;135(3):295-307. doi: 10.1111/bcpt.14046.Mas S, Gassò P, Alvarez S, et al. Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes. Pharmacogenet Genomics. 2011 Sep;21(9):531-8. doi: 10.1097/FPC.0b013e328348c6db.Mas S, Gassò P, Alvarez S, et al. Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes. Pharmacogenet Genomics. 2011 Sep;21(9):531-8. doi: 10.1097/FPC.0b013e328348c6db.Luo JQ, He FZ, Luo ZY, et al. Rs495828 polymorphism of the ABO gene is a predictor of enalapril-induced cough in Chinese patients with essential hypertension. Pharmacogenet Genomics. 2014 Jun;24(6):306-13. doi: 10.1097/FPC.0000000000000050.Luo JQ, He FZ, Luo ZY, et al. Rs495828 polymorphism of the ABO gene is a predictor of enalapril-induced cough in Chinese patients with essential hypertension. Pharmacogenet Genomics. 2014 Jun;24(6):306-13. doi: 10.1097/FPC.0000000000000050.Gu W, Li Z, Wang Z, et al. Association of the bradykinin receptors genes variants with hypertension: a case-control study and meta-analysis. Clin Exp Hypertens. 2016;38(1):100-6. doi: 10.3109/10641963.2015.1060989.Gu W, Li Z, Wang Z, et al. Association of the bradykinin receptors genes variants with hypertension: a case-control study and meta-analysis. Clin Exp Hypertens. 2016;38(1):100-6. doi: 10.3109/10641963.2015.1060989.Li YY, Lu XZ, Wang H, et al. ADRB3 Gene Trp64Arg Polymorphism and Essential Hypertension: A Meta-Analysis Including 9,555 Subjects. Front Genet. 2018 Apr 4;9:106. doi: 10.3389/fgene.2018.00106.Li YY, Lu XZ, Wang H, et al. ADRB3 Gene Trp64Arg Polymorphism and Essential Hypertension: A Meta-Analysis Including 9,555 Subjects. Front Genet. 2018 Apr 4;9:106. doi: 10.3389/fgene.2018.00106.Masilela C, Pearce B, Ongole JJ, et al. Cross-sectional study of the association of 5 single nucleotide polymorphisms with enalapril treatment response among South African adults with hypertension. Medicine (Baltimore). 2021 Nov 19;100(46):e27836. doi: 10.1097/MD.0000000000027836.Masilela C, Pearce B, Ongole JJ, et al. Cross-sectional study of the association of 5 single nucleotide polymorphisms with enalapril treatment response among South African adults with hypertension. Medicine (Baltimore). 2021 Nov 19;100(46):e27836. doi: 10.1097/MD.0000000000027836.Anthony EG, Richard E, Lipkowitz MS, Bhatnagar V. Association of the ADRB2 (rs2053044) polymorphism and angiotensin-converting enzyme-inhibitor blood pressure response in the African American Study of Kidney Disease and Hypertension. Pharmacogenet Genomics. 2015 Sep;25(9):444-9. doi: 10.1097/FPC.0000000000000154.Anthony EG, Richard E, Lipkowitz MS, Bhatnagar V. Association of the ADRB2 (rs2053044) polymorphism and angiotensin-converting enzyme-inhibitor blood pressure response in the African American Study of Kidney Disease and Hypertension. Pharmacogenet Genomics. 2015 Sep;25(9):444-9. doi: 10.1097/FPC.0000000000000154.Luo JQ, Wang LY, He FZ, et al. Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment. Pharmacogenomics. 2014 Feb;15(2):201-8. doi: 10.2217/pgs.13.173.Luo JQ, Wang LY, He FZ, et al. Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment. Pharmacogenomics. 2014 Feb;15(2):201-8. doi: 10.2217/pgs.13.173.Ma L, Zeng L, Wang X. MTHFR C677T gene polymorphism in patients with coronary heart disease and hypertension treated with enalapril and folic acid: implications for prognosis. Cell Mol Biol (Noisy-le-grand). 2024 Oct 8;70(9):142-147. doi: 10.14715/cmb/2024.70.9.20.Ma L, Zeng L, Wang X. MTHFR C677T gene polymorphism in patients with coronary heart disease and hypertension treated with enalapril and folic acid: implications for prognosis. Cell Mol Biol (Noisy-le-grand). 2024 Oct 8;70(9):142-147. doi: 10.14715/cmb/2024.70.9.20.Wu Y, Yang H, Xiao C. Genetic association study of prolylcarboxypeptidase polymorphisms with susceptibility to essential hypertension in the Yi minority of China: A case-control study based on an isolated population. J Renin Angiotensin Aldosterone Syst. 2020 AprJun;21(2):1470320320919586. doi: 10.1177/1470320320919586.Wu Y, Yang H, Xiao C. Genetic association study of prolylcarboxypeptidase polymorphisms with susceptibility to essential hypertension in the Yi minority of China: A case-control study based on an isolated population. J Renin Angiotensin Aldosterone Syst. 2020 AprJun;21(2):1470320320919586. doi: 10.1177/1470320320919586.Zhang Y, Hong XM, Xing HX, et al. E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients. Chin Med J (Engl). 2009 Oct 20;122(20):2461-5.Zhang Y, Hong XM, Xing HX, et al. E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients. Chin Med J (Engl). 2009 Oct 20;122(20):2461-5.F. P. Guengerich Human Cytochrome P450 Enzymes. Chapter 10, P. 377-530. In:Cytochrome P450: Structure, Mechanism, and Biochemistry. Ed by P.R. Ortiz de Montellano, Kluwer Academic/Plenum Publishers, New York, 2005.F. P. Guengerich Human Cytochrome P450 Enzymes. Chapter 10, P. 377-530. In:Cytochrome P450: Structure, Mechanism, and Biochemistry. Ed by P.R. Ortiz de Montellano, Kluwer Academic/Plenum Publishers, New York, 2005.Yu HM, Lin SG, Liu GZ, et al. Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors. Clin Pharmacol Ther. 2006 Jun;79(6):581-9. doi: 10.1016/j.clpt.2006.02.007.Yu HM, Lin SG, Liu GZ, et al. Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors. Clin Pharmacol Ther. 2006 Jun;79(6):581-9. doi: 10.1016/j.clpt.2006.02.007.Wang X, Wang G, Shi J, et al. CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors. Pharmacogenomics J. 2016 Jun;16(3):220-30. doi: 10.1038/tpj.2015.42.Wang X, Wang G, Shi J, et al. CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors. Pharmacogenomics J. 2016 Jun;16(3):220-30. doi: 10.1038/tpj.2015.42.Hussain M, Basheer S, Khalil A, et al. Pharmacogenetic study of CES1 gene and enalapril efficacy. J Appl Genet. 2024 Sep;65(3):463-471. doi: 10.1007/s13353-024-00831-w.Hussain M, Basheer S, Khalil A, et al. Pharmacogenetic study of CES1 gene and enalapril efficacy. J Appl Genet. 2024 Sep;65(3):463-471. doi: 10.1007/s13353-024-00831-w.Her LH, Wang X, Shi J, et al. Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol. 2021 Dec;87(12):4691-4700. doi: 10.1111/bcp.14888.Her LH, Wang X, Shi J, et al. Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol. 2021 Dec;87(12):4691-4700. doi: 10.1111/bcp.14888.

The authors declare that there are no conflicts of interest present.